This review looked at the use of aptamers and aptamer-drug conjugates as treatments for cancer. The source material did not report the specific number of patients involved, the exact setting where these treatments were used, or the detailed results of the review.
Because the publication is a review rather than a direct clinical trial, specific findings about how well these treatments work or their safety profile were not provided in the available information. There were no reported adverse events, serious side effects, or details on how many patients stopped the treatment.
Readers should understand that without specific data on outcomes or safety, it is difficult to determine the real-world effectiveness of these therapies. The main reason to be cautious is the lack of reported details regarding the population studied and the primary results. Ultimately, this review highlights the potential interest in these agents but does not offer concrete evidence on their benefits or risks for cancer patients.